PDS Biotech’s Q2 2024 Update: Clinical Progress
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
- Latest
- Trending
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Woodridge Police use VR for de-escalation, marking Illinois' first such use.
Discover promising biotech stocks with expert insights on market trends and innovative drugmakers worth your investment.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.
Roche is evaluating options for its $1.9 billion investment in Flatiron Health, potentially including divestment.
DaVita increases 2024 profit outlook due to high demand for kidney dialysis services, boosting shares by 3% in aftermarket trade.
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.